Clinical Trials Advances For Better Health Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$8,012,612.00
Summary
The NHMRC Clinical Trials Centre (CTC) aims to use clinical trials and methodological research in trials to improve health in Australia and internationally. Its research program will initiate major new clinical trials and a comprehensive program of research into trial methods, biostatistical analysis, health outcome analysis and decision analysis. Patient preferences and decision making, particularly in cancer, will be a focus. CTC uses data from its own and other clinical trials in combined ana ....The NHMRC Clinical Trials Centre (CTC) aims to use clinical trials and methodological research in trials to improve health in Australia and internationally. Its research program will initiate major new clinical trials and a comprehensive program of research into trial methods, biostatistical analysis, health outcome analysis and decision analysis. Patient preferences and decision making, particularly in cancer, will be a focus. CTC uses data from its own and other clinical trials in combined analyses to arrive at better evidence. The NHMRC program grant will allow important research studies to be integrated with trials funded from industry and other sources and will maintain the CTC’s internationally competitive research team at the cutting edge of new trial methods and systems.Read moreRead less
Depressive And Bipolar Disorders: Evaluating Determinants Of Onset, Recovery And Treatment Resistance
Funder
National Health and Medical Research Council
Funding Amount
$7,861,447.00
Summary
The depressive disorders, including bipolar disorder, are highly prevalent in the Australian community. These illnesses may be chronic or relapsing, may impair the capacity to work and can be resistant to treatment. The research team addresses this public health and clinical problem by undertaking a number of studies pursuing factors influencing predisposition and onset to disorder, clarifying the effectiveness of new treatments, and investigating factors predictive of treatment response and res ....The depressive disorders, including bipolar disorder, are highly prevalent in the Australian community. These illnesses may be chronic or relapsing, may impair the capacity to work and can be resistant to treatment. The research team addresses this public health and clinical problem by undertaking a number of studies pursuing factors influencing predisposition and onset to disorder, clarifying the effectiveness of new treatments, and investigating factors predictive of treatment response and resistance.Read moreRead less
Epilepsy: Molecular Basis And Mechanisms In The Era Of Functional Genomics
Funder
National Health and Medical Research Council
Funding Amount
$12,062,533.00
Summary
The team comprises of neurologists with a special interest in epilepsy (both adult and child) molecular geneticists, physiologists and brain imaging specialists. The team leads the world in the discovery of the genetic causes of epilepsy and epilepsy associated with intellectual disability. The team will continue to identify the genes underlying epilepsy, and study how genetic variations result in the development of seizures and will continue to develop advanced imaging techniques for these stud ....The team comprises of neurologists with a special interest in epilepsy (both adult and child) molecular geneticists, physiologists and brain imaging specialists. The team leads the world in the discovery of the genetic causes of epilepsy and epilepsy associated with intellectual disability. The team will continue to identify the genes underlying epilepsy, and study how genetic variations result in the development of seizures and will continue to develop advanced imaging techniques for these studies. This will include extensive laboratory studies, including the development of mice with the exact mutations that we find in the human condition. Stateof-the-art imaging techniques with magnetic resonance and positron emission tomography are used in human subjects to further understand the effects of the mutations on the structure and function of the brain. This will allow deep understanding of how seizures develop and may lead to new diagnostic methods and treatments. The laboratory and clinical aspects of the research are tightly integrated in this internationally leading collaborative program.Read moreRead less
IMPROVING STROKE OUTCOMES: NEW TARGETS AND THERAPIES
Funder
National Health and Medical Research Council
Funding Amount
$7,212,064.00
Summary
Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using ....Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using the clot dissolving agent tPA to extend the time during which the drug may be effective beyond the three-hours currently used. In the next phase of our program we plan to expand the basic science component to identify parts of brain cells (axons and dendrites) which may yield important information about new drugs to protect the brain. We will use our novel summary data technique to test drugs in animal models more appropriate to the human stroke paradigm than have been used in the past In clinical studies we will follow our theme of identifying new targets for therapy using sophisticated PET and MRI imaging techniques, both in patients who are at great risk of stroke recurrence after a minor warning stroke and those with stroke caused by bleeding within the brain. These studies will provide information about predictors of recurrent and worsening stroke which may be modified by new therapies. The final stage in identifying new therapies is the Phase III clinical trial. We will complete one of these in which the most appropriate drug preventing further strokes in a major new stroke subtype will be identified. Toward the end of the program, we will commence phase 3 studies of drugs we have selected as being most likely to protect the brain based on our animal experiments. The main benefit of this unique collaborative research model is to efficiently identify new therapies to reduce the burden of stroke, currently the second most common cause of death globally.Read moreRead less
Individual Decision Making, Welfare Measurement And Policy Evaluation In The Health Sector: A Microeconometric Approach
Funder
National Health and Medical Research Council
Funding Amount
$6,968,101.00
Summary
This proposed program of research will contribute to the development of economics and health economics internationally. It provides an exciting opportunity to bring together scholars across economics at the forefront of the discipline internationally, who are researchers with extensive experience in the practical application of research results in shaping policy directions. The approach will fill the repeatedly identified gap in policy relevant health services research at the system level in Aus ....This proposed program of research will contribute to the development of economics and health economics internationally. It provides an exciting opportunity to bring together scholars across economics at the forefront of the discipline internationally, who are researchers with extensive experience in the practical application of research results in shaping policy directions. The approach will fill the repeatedly identified gap in policy relevant health services research at the system level in Australia. The immediate outcomes of the research program will be information on specific health policy issues, in terms of the drivers of cost and utilization, access and equity.Read moreRead less
Proteases, Their Inhibitors And Receptors In Degenerative Disease
Funder
National Health and Medical Research Council
Funding Amount
$5,843,388.00
Summary
Many of the themes of this program are aimed at understanding the molecular basis of several important degenerative diseases that in particular affect the ageing population. These include osteoporosis, arthritis, periodontal disease, wasting diseases of muscle and inherited disorders such as antitrypsin deficiency. The five CI’s on this application have formed a collaborative network since 1996. Dr Whisstock is a bioinformatician and structural biologist with a research focus on the serpin super ....Many of the themes of this program are aimed at understanding the molecular basis of several important degenerative diseases that in particular affect the ageing population. These include osteoporosis, arthritis, periodontal disease, wasting diseases of muscle and inherited disorders such as antitrypsin deficiency. The five CI’s on this application have formed a collaborative network since 1996. Dr Whisstock is a bioinformatician and structural biologist with a research focus on the serpin superfamily of protease inhibitors and their protease partners. He is currently the scientific director of the Victorian Bioinformatics Consortium and an NHMRC Senior Research Fellow. Dr Bird is an NHMRC Senior Research Fellow who discovered the intracellular branch of the serpin superfamily and formulated the hypothesis that describes their function. A-Prof Mackie is a world expert in the field of musculoskeletal biology and pathology. Dr Bottomley is a Senior Logan Fellow and RD Wright Fellow whose research focuses upon how proteins misfold and lead to disease. Dr Pike is an enzymologist whose research area encompasses a wide range of bacterial and mammalian proteases involved in the pathology of human disease. Each individual in this team brings different skills which makes this a very important and powerful collaboration. The research is extensive and involves protein folding, enzyme kinetics, molecular modelling, structural biology, bioinformatics, cell biology and pathology, enzyme kinetics and drug design. Collectively the CI’s have a total of 154 papers since 1998, of which a third include two or more of the CI’s as co-authors. Currently the team holds over >$5 million in grant funding. The team is augmented by four P.I.s: Dr Buckle is a talented structural biologist; Dr Scott is a molecular cell biologist who holds an NHMRC CJ Martin Fellow; Dr Garcia de la Banda is a computer scientist based at Monash and Dr Grigoryev is a world expert in chromatin condensation based at Penn State University (USA).Read moreRead less
Tropical Infectious Diseases - Pathogenisis And Vaccine Research
Funder
National Health and Medical Research Council
Funding Amount
$7,311,989.00
Summary
The diseases on which three themes of the work proposed centre, malaria, streptococcal diseases and scabies are infectious diseases largely affecting indigenous people in various parts of the world on a massive scale, for which there are no vaccines. The aim of the work is to develop vaccines or other biological prevention measures against each of these diseases and the problems that need to be solved are similar. The team includes senior experts on thebiology of infectious diseases with long hi ....The diseases on which three themes of the work proposed centre, malaria, streptococcal diseases and scabies are infectious diseases largely affecting indigenous people in various parts of the world on a massive scale, for which there are no vaccines. The aim of the work is to develop vaccines or other biological prevention measures against each of these diseases and the problems that need to be solved are similar. The team includes senior experts on thebiology of infectious diseases with long histories of collaboration as well as younger members with impressive credentials that are new to the collaboration. The fourth theme of the work proposed is concerned with inventive new ways of making such vaccines by novelchemical methods. It has already been the subject of published collaborative work onstreptococcal disease and is equally applicable to the other themes.Read moreRead less
A major obstacle to the development of safer and more effective pain treatments is the poorly defined nature of the different pathways involved in chronic pain. The applicant team bring together a unique set of research expertise in using neurotoxins to define, at the molecular level, how the nervous system functions. The applicants also share a common interest in understanding and improving treatments for pain, especially chronic pain which continues to remain poorly managed Through a focus on ....A major obstacle to the development of safer and more effective pain treatments is the poorly defined nature of the different pathways involved in chronic pain. The applicant team bring together a unique set of research expertise in using neurotoxins to define, at the molecular level, how the nervous system functions. The applicants also share a common interest in understanding and improving treatments for pain, especially chronic pain which continues to remain poorly managed Through a focus on pain research, the Program will significantly enhance the scope of existing multidisciplinary collaborations between the Cis Lewis Alewood, Adams and Christie, which have already made a considerable impact in the fields of pharmacology and neuroscience. The CIs also have considerable experience in the development of pain therapeutics, having discovered two conopeptides now under commercial development with AMRAD (AM336) and Xenome Ltd (Xen2174). This Program will discover and use highly selective conopeptides such as these to dissect the pharmacology of peripheral pain pathways and their projections into the central nervous system, and to identify and characterise new targets amenable to drug intervention. The long-term goal of the Program is to discover new targets in pain pathways and develop conopeptides that act on these targets in animal models of chronic pain. These molecules will be optimised within the Program to the point where they can be considered for pre-clinical development in collaboration with commercial partners.Read moreRead less